Clinical trials: Pegfilgrastim
Diabetes Mellitus, Type 1
Reversing Type 1 Diabetes After it is Established
The primary purpose of this study is to determine if giving the combination therapy consisting of Thymoglobulin® (ATG) and Neulasta® (GCSF) to patients with established Type 1 Diabetes (T1D) is safe and secondarily, if the ATG…
- Trial name
- NCT01106157
- Testing
- Anti-Thymocyte Globin (ATG), Pegylated GCSF
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Florida
Breast Cancer
Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients
Background: The investigators previously studied the addition of low-dose, short-course sunitinib to pre-operative chemotherapy in the neoadjuvant setting in newly diagnosed breast cancer patients with measurable primary breast…
- Trial name
- NCT02790580
- Testing
- Dose-dense doxorubicin/cyclophosphamide + sunitinib, Dose-dense doxorubicin/cyclophosphamide
- Where
- Singapore
- Volunteers
- 98 people
- Sponsor
- National University Hospital, Singapore
Advanced Cancer
A Dose-Escalation Study for Patients With Advanced Cancer
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
- Trial name
- NCT01214642
- Testing
- pegfilgrastim, LY2523355
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Mantle Cell Lymphoma
Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of previous treatment.
- Trial name
- BATMAN (NCT02840539)
- Testing
- Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Seoul National University Hospital
Neutropenia
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia.
- Trial name
- PEG-rhG-CSF (NCT01918241)
- Testing
- pegfilgrastim,30mcg/kg, pegfilgrastim, 60mcg/kg, pegfilgrastim, 100mcg/kg
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Breast Cancer Metastatic
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients with metastatic Triple Nagative Breast Cancer who have received at least one, and no more than two, prior standard of care chemotherapy regimens
- Trial name
- NCT06616987
- Testing
- Sacituzumab Govitecan with pegfilgrastim
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yeon Hee Park
Non-Small Cell Lung Cancer
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC
A single arm, open-label phase II is appropriate to evaluate the efficacy and safety of dose - dense combination of paclitaxel with cisplatin supported by pegfilgrastim for neo-adjuvant chemotherapy in this patient population.
- Trial name
- NCT00291850
- Testing
- Paclitaxel, Cisplatin, Pegfilgrastim
- Where
- 5 sites in Austria, Hungary and 1 more
- Volunteers
- 50 people
- Sponsor
- Central European Cooperative Oncology Group
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07059611
- Testing
- RP2, 5-Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Bone Cancer, Ewing's Sarcoma
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
The outcome of patients with metastatic Ewings Sarcoma is poor with current standard of care chemotherapy, with less than 30% survival.
- Trial name
- NCT01313884
- Testing
- Irinotecan, Vincristine, Temozolomide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer.
- Conditions
- Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Posterior Urethral Cancer, Recurrent Bladder Cancer
- Trial name
- NCT01639521
- Testing
- cisplatin, gemcitabine hydrochloride, methotrexate
- Sponsor
- University of Southern California
Chronic Lymphocytic Leukemia
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and mitoxantrone plus rituximab, with the growth factor pegylated filgrastim, will improve the response to treatment…
- Trial name
- NCT00254410
- Testing
- Fludarabine, Cyclophosphamide, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Rhabdomyosarcoma
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
This is a phase II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating…
- Trial name
- NCT06023641
- Testing
- Vincristine, Dactinomycin, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- St. Jude Children's Research Hospital
Healthy
Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim
The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and…
- Trial name
- M-PRP (NCT05573386)
- Testing
- Filgrastim, Pegfilgrastim
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Andrews Research & Education Foundation
Breast Cancer, Lymphoma
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
Purpose: To evaluate the preventative effects of pregabalin on pegfilgrastim-induced bone pain in cycle 1. Because granulocyte colony stimulating factor (G-CSF) receptors are found at nerve endings which modulate the pain signal…
- Conditions
- Breast Cancer, Lymphoma, Pain
- Trial name
- NCT03407430
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Diffuse Large B Cell Lymphoma, DLBCL
Split-Dose R-CHOP for Older Adults With DLBCL
This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an…
- Conditions
- Diffuse Large B Cell Lymphoma, DLBCL, Cancer
- Trial name
- NCT03943901
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Wisconsin, Madison
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Fallopian Tube Carcinoma, Infectious Disorder
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
This phase I trial is studying the side effects of giving carboplatin and paclitaxel together with pegfilgrastim in treating patients with stage III or stage IV ovarian epithelial, fallopian tube, primary peritoneal, or…
- Conditions
- Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma
- Trial name
- NCT00352300
- Testing
- Adjuvant Therapy, Carboplatin, Paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 43 people
- Sponsor
- Gynecologic Oncology Group
Soft-tissue Sarcoma, Triple Negative Breast Cancer
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small…
- Conditions
- Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT07064018
- Testing
- Spedox-6, Pegfilgrastim, Filgrastim
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, Irvine
Chemotherapy Associated Neutropenia, Breast Cancer
Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim
The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Trial name
- PIONEER (NCT01519700)
- Testing
- EP2006, Filgrastim
- Where
- 26 sites in Czechia, Hungary and 4 more
- Volunteers
- 218 people
- Sponsor
- Sandoz
Breast Cancer
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070564
- Testing
- pegfilgrastim, AC regimen, cyclophosphamide
- Where
- 542 sites in United States, Canada and 1 more
- Volunteers
- 3,294 people
- Sponsor
- SWOG Cancer Research Network